803607AD2
Sarepta Therapeutics, Inc.
Could not find a ticker for this position, may be a filing error
A maker of precision genetic medicines for rare diseases, Sarepta Therapeutics develops treatments for Duchenne muscular dystrophy (DMD) and other neuromuscular conditions, including Exondys 51, the first therapy ever approved for DMD. The company began in 1980 in Corvallis, Oregon, as AntiVirals, Inc., later became AVI BioPharma, and took the name Sarepta in 2012. The name comes from the biblical town of Sarepta, where the prophet Elijah performed miracles.
CONVERTIBLEUnderlying: SRPTCUSIP: 803607AD2HealthcareUS1 derivative reporter
1.25% Convertible Senior Notes due 2027
No tracked superinvestor held this security as stock in this period — only the derivative positions below reference it.
Derivative Reporters
Investor
Kind
13F reported value
Quantity
Change
